

DB=PGPB,USPT; PLUR=YES; OP=AND

L10 18

192 L10

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=AND

L9 L8

8 L9

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND

L8 L7 and hepatitis adj C

200 L8

L7 artem\$

10253 L7

DB=PGPB,USPT; PLUR=YES; OP=AND

L6 artem\$

3892 L6

L5 L1 and flavivir\$

3 L5

L4 L2 and flavivir\$

1 L4

L3 L2 and hepatitis

2 L3

L2 L1 and artem\$

47 L2

L1 514/450.ccis.

917 L1

END OF SEARCH HISTORY

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:573663 CAPLUS
DOCUMENT NUMBER: 119:173663
TITLE: Experimental study of inhibitory effect of the four
traditional Chinese herb medicines on epidemic
hemorrhagic fever virus
AUTHOR(S): Zheng, Xuanhe; Tang, Xiaopeng; Su, Xianshi
CORPORATE SOURCE: 2nd Affil. Hosp., Hunan Med. Univ., Changsha, Peop.
Rep. China
SOURCE: Hunan Yike Daxue Xuebao (1993), 18(2), 165-7
CODEN: HYXBET; ISSN: 1000-5625
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB A laboratory observation of inhibitory effect of artemether, glycyrrhizin,
houttuynia and bupleura on epidemic hemorrhagic fever virus (EHFV)
infection is reported. The infection rates of the suckling mice treated
with artemether and glycyrrhizin were much lower than that in the control
group. The distribution of EHFV in the suckling mice on houttuynia and
bupleura was different from that in the control group. It is indicated
that artemether and glycyrrhizin can markedly prevent the EHFV infection
in suckling mice. Moreover, houttuynia and bupleura might inhibit EHFV
infection to some extent.

P

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
Term:	L19 not Capillary adj artemisia <div style="float: right; margin-top: -20px;"> <input style="width: 20px; height: 20px; border: 1px solid black; border-radius: 50%; background-color: transparent; font-size: 10px; line-height: 10px; text-align: center; vertical-align: middle; margin-right: 5px;" type="button" value="Up"/> <input style="width: 20px; height: 20px; border: 1px solid black; border-radius: 50%; background-color: transparent; font-size: 10px; line-height: 10px; text-align: center; vertical-align: middle;" type="button" value="Down"/> </div>
Display:	10 <input type="text"/> Documents in <u>Display Format:</u> <input type="text"/> Starting with Number <input type="text" value="1"/>
Generate: <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	
<input style="border: 1px solid black; padding: 2px 10px; margin-right: 10px;" type="button" value="Search"/> <input style="border: 1px solid black; padding: 2px 10px; margin-right: 10px;" type="button" value="Clear"/> <input style="border: 1px solid black; padding: 2px 10px;" type="button" value="Interrupt"/>	

Search History

DATE: Monday, June 04, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L22</u>	L19 not Capillary adj artemisia	40	<u>L22</u>
<u>L21</u>	L20 and artemisinin	6	<u>L21</u>
<u>L20</u>	L19	96	<u>L20</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L19</u>	I7 and hepatitis	566	<u>L19</u>
<i>DB=USPT; PLUR=YES; OP=AND</i>			
<u>L18</u>	I7 and hepatitis	118	<u>L18</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L17</u>	5246930	4	<u>L17</u>
<u>L16</u>	L14 and (virus or antivir\$)	28	<u>L16</u>
<u>L15</u>	L14 and hepatitis	6	<u>L15</u>
<u>L14</u>	qinghao or qinghaosu	128	<u>L14</u>
<u>L13</u>	artemisia adj anuual	0	<u>L13</u>
<u>L12</u>	(artemisia or A) adj anuual	0	<u>L12</u>
<i>DB=USPT; PLUR=YES; OP=AND</i>			
<u>L11</u>	L10	25	<u>L11</u>

=> d hist

(FILE 'HOME' ENTERED AT 10:40:35 ON 04 JUN 2007)

FILE 'REGISTRY' ENTERED AT 10:41:31 ON 04 JUN 2007

L1 99 S ARTEMISININ
L2 1 S ARTEMETHER/CN
L3 1 S ARTEETHER/CN
L4 1 S ARTESUNATE/CN

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:43:54 ON 04 JUN 2007

L5 7624 S ARTEMISININ
L6 67 S L5 AND HEPATITIS
L7 53 DUPLICATE REM L6 (14 DUPLICATES REMOVED)
L8 10 S L7 AND HEPATITIS (W) C
L9 21 S L7 AND PY<=2003
L10 5 S L9 AND (VIRUS OR ANTIVIRAL)

FILE 'STNGUIDE' ENTERED AT 10:50:53 ON 04 JUN 2007

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:52:09 ON 04 JUN 2007
L11 8913 S L1 OR L2 OR L3 OR L4
L12 80 S L11 AND HEPATITIS
L13 29 S L12 AND PY<=2003
L14 28 DUPLICATE REM L13 (1 DUPLICATE REMOVED)
L15 24 S L14 NOT L10

FILE 'STNGUIDE' ENTERED AT 10:58:44 ON 04 JUN 2007

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 11:00:04 ON 04 JUN 2007
L16 9 S L11 AND FLAVIVIRID?
L17 6 DUPLICATE REM L16 (3 DUPLICATES REMOVED)
L18 6 S L17 NOT L10
L19 3 S L17 NOT L8


L23 ANSWER 6 OF 31 : CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:234337 CAPLUS <<LOGINID::20070604>>
 DOCUMENT NUMBER: 130:267461
 TITLE: Preparation of artemisin derivative containing phenyl
 and heterocyclic radicals
 INVENTOR(S): Li, Yang; Yang, Yonghua; Liang, Jie; Shan, Feng; Wu,
 Guangshao
 PATENT ASSIGNEE(S): Shanghai Inst. of Materia Medica, Chinese Academy of
 Sciences, Peop. Rep. China
 SOURCE: Faming Zhanli Shengqing Gongkai Shuomingshu, 17 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1122806	A	19960522	CN 1994-113982	19941109 <--
CN 1049435	B	20000216	CN 1994-113982	19941109

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

GI



AB Title artemisin derivs. [I; X = O, NH; R = Ph, R3 substituted Ph, 2 same or different R3 and R4 substituted Ph, the heterocyclic radical is alkali adenyl, thymine, cytidine, uracil, and their R3 substituted groups, triazo-, and CONH2 or R3 substituted triazo-; R3 = R4 = hydroxy, alkoxy (C1-C4), alkyl (C1-C4), COOCH3, COOC2H5, NHCOCH3, nitro, halogen (F, Cl, Br, I), dihydrogen artemisin radical] are prepared by reaction of dihydrogen artemisin, dihydrogen artemisin acetate, dihydrogen artemisin trifluoroacetate, and anilines with R3 substituted groups, R3 or R3 and R4 substituted phenols, Ph compound, heterocyclic compound or its silicone ether derivs. in the presence of acidic catalyst, boron trifluoride etherate, SnCl4, TiCl4, trifluoroacetic acid, p-Me benzenesulfonic acid, trimethylsilyl triflate, H2SO4 and H3PO4 and polar solvent, alkyl halide, Et ether, acetonitrile, THF, pyridine, triethylamine, and methyl-sulfoxide at -10° to 40°. Phenylamino artemisin, 3-chloro-phenylamino artemisin, 4-artemisin, 3-nitro-phenoxy artemisin, 4-methoxy-phenoxy artemisin, 4-(methoxycarbonyl)-phenoxy artemisin, 4-acetamino-phenoxy artemisin, tris(artemisin) phloroglucin, 5-hydroxy-1,3-bis(artemisin) benzenediol, adenyl artemisin, 5-fluoro-uracil artemisin, 3-aminocarbonyl triazo artemisin, and 2,4-dimethoxyphenyl artemisin were prepared as antitumor, antiviral, and antiparasitic agents.